Entera Bio Ltd
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
ENTX$3.25+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(U.S. dollars in thousands, except share and per share data)
| 2023 | 2022 | |
|---|---|---|
| REVENUES | - | 134 |
| COST OF REVENUES | - | 101 |
| GROSS PROFIT | - | 33 |
| OPERATING EXPENSES: | ||
| Research and development | 4,510 | 5,848 |
| General and administrative | 4,430 | 7,253 |
| Other income | (49) | (51) |
| TOTAL OPERATING EXPENSES | 8,891 | 13,050 |
| OPERATING LOSS | 8,891 | 13,017 |
| FINANCIAL INCOME, net | (31) | (83) |
| LOSS BEFORE INCOME TAX | 8,860 | 12,934 |
| INCOME TAX EXPENSES | 29 | 137 |
| NET LOSS | 8,889 | 13,071 |
| LOSS PER SHARE BASIC AND DILUTED | 0.31 | 0.45 |
| WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE | 29,007,794 | 28,808,090 |
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.